Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
NCT00281788
Completed
RATIONALE: Drugs used in chemotherapy, such as capecitabine, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with carboplatin, paclitaxel, and radia... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2013
Locations: Duke Comprehensive Cancer Center, Durham, North Carolina
Conditions: Esophageal Cancer
Register for Updates
Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer
NCT00581971
Completed
This is a single-institution, open-label, non-randomized phase IB/II trial of celecoxib administered concurrently with carboplatin, paclitaxel, and radiation therapy in patients with locally advanced or recurrent squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
03/13/2013
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cancer
Register for Updates
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
NCT00040872
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapie... Read More
Gender:
ALL
Ages:
50 years and below
Trial Updated:
03/06/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma
Register for Updates
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
NCT00288041
Completed
This phase II trial is studying how well giving bortezomib together with paclitaxel and carboplatin works in treating patients with metastatic melanoma. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may help paclitaxel and carboplatin kill more tum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2013
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma
Register for Updates
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
NCT00429182
Completed
The goal of this clinical research study is to learn the relationship of high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast cancer. The study also will investigate the role of CTCs in breast cancer.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2013
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
Register for Updates
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00075751
Completed
Phase II trial to study the effectiveness of combining bortezomib with gemcitabine and carboplatin in treating patients who have advanced or recurrent non-small cell lung cancer that has not been previously treated with chemotherapy. Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Bortezomib may al... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2013
Locations: Southwest Oncology Group, San Antonio, Texas
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
NCT00021060
Completed
Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with a monoclonal antibody may kill more tumor cells. This randomized phase II/III trial is to see if combination chemotherapy w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2013
Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts
Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
NCT00301028
Completed
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kil... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
02/26/2013
Locations: M.D. Anderson Cancer Center at University of Texas, Houston, Texas
Conditions: Head and Neck Cancer
Register for Updates
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
NCT01016054
Terminated
This is a parallel arm study to evaluate AGS-8M4 administered in combination with chemotherapy in subjects with ovarian cancer. AGS-8M4 will be administered as an IV infusion until disease worsens.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/26/2013
Locations: Not set, Duarte, California
Conditions: Carcinoma, Ovarian Cancer, Ovarian Diseases, Ovarian Neoplasms
Register for Updates
Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer
NCT00529022
Completed
The goal of this clinical research study is to find out if giving azacitidine with valproic acid plus carboplatin can help control advanced cancer. The safety of this treatment will be studied as well. Researchers will also collect some extra blood samples for molecular marker studies (studies that may help researchers predict how participants respond to the combined therapy). There were to be two phases of this study: a Phase 1 portion to find acceptable doses of the study drug combination, an... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/19/2013
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumors
Register for Updates
S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer
NCT00004137
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus filgrastim in treating pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2013
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +84 locations
Conditions: Lung Cancer
Register for Updates
Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
NCT00025389
Completed
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy before surgery may may shrink the tumor so that it can be removed. PURPOSE: This ph... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2013
Locations: University of Chicago Cancer Research Center, Chicago, Illinois +1 locations
Conditions: Lung Cancer
Register for Updates